These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6463953)

  • 21. [Drug surveillance: the concept, the need and methods].
    Moreno González A
    An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138
    [No Abstract]   [Full Text] [Related]  

  • 22. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 23. [Detection of drug side effects at the Heidelberg Medical Clinic].
    Jacubeit T; Drisch D
    Verh Dtsch Ges Inn Med; 1989; 95():690-3. PubMed ID: 2603505
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 25. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidemiologic assessment of adverse drug effects.
    Stern RS
    Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comprehensive detection of severe, potentially life-threatening drug side effects].
    Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
    Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
    [No Abstract]   [Full Text] [Related]  

  • 28. [Is establishment of causality in drug surveillance reliable?].
    Evreux JC
    Therapie; 1984; 39(4):437-8. PubMed ID: 6484888
    [No Abstract]   [Full Text] [Related]  

  • 29. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
    Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug safety and the role of clinical pharmacology in the safe use of therapeutics.
    Honig PK
    Clin Pharmacol Ther; 2009 Mar; 85(3):225-8. PubMed ID: 19223873
    [No Abstract]   [Full Text] [Related]  

  • 31. [Safety pharmacology: central nervous system].
    Rambert FA
    Therapie; 2000; 55(1):55-61. PubMed ID: 10860002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. With more follow-up.
    Prescrire Int; 2011 Feb; 20(113):32. PubMed ID: 21488585
    [No Abstract]   [Full Text] [Related]  

  • 33. [30 years' spontaneous recording systems of German physicians--results and experiences].
    Kimbel KH
    Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
    [No Abstract]   [Full Text] [Related]  

  • 34. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The three pillars of clinical pharmacology].
    Jaillon P
    Therapie; 2002; 57(1):3-5. PubMed ID: 12090144
    [No Abstract]   [Full Text] [Related]  

  • 36. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 38. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 40. [Limitations of spontaneous reporting and ways of improving the quality of the data].
    Boschetti C; Borghi C; Canti D; Cortellaro M
    Clin Ter; 1988 Dec; 127(6):421-9. PubMed ID: 2977315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.